**Core Concept**
The question is testing the student's knowledge of the pharmacokinetics of neuraminidase inhibitors, specifically how they are eliminated from the body. Neuraminidase inhibitors are a class of antiviral medications used to treat influenza.

**Why the Correct Answer is Right**
The correct answer is Zanamivir (C). Zanamivir is a neuraminidase inhibitor that is excreted almost exclusively through the lungs, with minimal renal elimination. This is because it is administered via inhalation, allowing it to be absorbed directly into the bloodstream and then excreted through the lungs. This unique pharmacokinetic profile makes Zanamivir an ideal treatment for influenza, as it can act locally in the respiratory tract and minimize systemic side effects.

**Why Each Wrong Option is Incorrect**
* **Option A:** Oseltamivir (Tamiflu) is a neuraminidase inhibitor that is primarily metabolized by the liver and then excreted through the kidneys, so it does not have 100% renal elimination.
* **Option B:** Peramivir is another neuraminidase inhibitor that is primarily excreted through the kidneys, but not 100% of it is eliminated through the kidneys.
* **Option D:** Laninamivir is a neuraminidase inhibitor that is administered via inhalation, but it is not 100% eliminated through the kidneys.

**Clinical Pearl / High-Yield Fact**
It's essential for clinicians to understand the unique pharmacokinetic profiles of neuraminidase inhibitors, as this can impact dosing, administration routes, and potential side effects.

**Correct Answer:** C. Zanamivir.